Shuji Hasegawa
Kitakyushu, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
External Validation of a Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Patients Receiving Post-Docetaxel Second-Line Chemotherapy.
Journal: JMA journal
Published: October 27, 2021
Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study.
Journal: Prostate international
Published: October 08, 2020
A CASE OF RENAL CELL CARCINOMA THAT ONCE NIVOLUMAB HAD BEEN EFFECTIVE IN METASTATIC LESION AND MADE PRIMARY TUMOR RESECTABLE
Journal: Nihon Hinyokika Gakkai zasshi. The japanese journal of urology
Published: January 21, 2020
Prognostic significance of lactate dehydrogenase in cabazitaxel chemotherapy for castration-resistant prostate cancer: a multi-institutional study.
Journal: Anti-cancer drugs
Published: January 09, 2020
Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel.
Journal: Anticancer research
Published: November 18, 2019
Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study.
Journal: Cancer chemotherapy and pharmacology
Published: April 10, 2019
Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study.
Journal: Medical oncology (Northwood, London, England)
Published: December 17, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026